Literature DB >> 22398621

Profiling PARP inhibitors.

Philip Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22398621     DOI： 10.1038/nbt.2138

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

1.  Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme.

Authors:  P CHAMBON; J D WEILL; P MANDEL
Journal:  Biochem Biophys Res Commun       Date:  1963-04-02       Impact factor: 3.575

2.  Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation.

Authors:  Henning Kleine; Elzbieta Poreba; Krzysztof Lesniewicz; Paul O Hassa; Michael O Hottiger; David W Litchfield; Brian H Shilton; Bernhard Lüscher
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

3.  [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.

Authors:  Michael D Shultz; Christina A Kirby; Travis Stams; Donovan N Chin; Jutta Blank; Olga Charlat; Hong Cheng; Atwood Cheung; Feng Cong; Yun Feng; Pascal D Fortin; Tami Hood; Viraj Tyagi; Ming Xu; Bailin Zhang; Wenlin Shao
Journal:  J Med Chem       Date:  2012-02-01       Impact factor: 7.446

4.  Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.

Authors:  Elisabet Wahlberg; Tobias Karlberg; Ekaterina Kouznetsova; Natalia Markova; Antonio Macchiarulo; Ann-Gerd Thorsell; Ewa Pol; Åsa Frostell; Torun Ekblad; Delal Öncü; Björn Kull; Graeme Michael Robertson; Roberto Pellicciari; Herwig Schüler; Johan Weigelt
Journal:  Nat Biotechnol       Date:  2012-02-19       Impact factor: 54.908

Review 5.  Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.

Authors:  Prakash Jagtap; Csaba Szabó
Journal:  Nat Rev Drug Discov       Date:  2005-05       Impact factor: 84.694

6.  Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Authors:  Thomas D Penning; Gui-Dong Zhu; Viraj B Gandhi; Jianchun Gong; Xuesong Liu; Yan Shi; Vered Klinghofer; Eric F Johnson; Cherrie K Donawho; David J Frost; Velitchka Bontcheva-Diaz; Jennifer J Bouska; Donald J Osterling; Amanda M Olson; Kennan C Marsh; Yan Luo; Vincent L Giranda
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

7.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Authors:  Shih-Min A Huang; Yuji M Mishina; Shanming Liu; Atwood Cheung; Frank Stegmeier; Gregory A Michaud; Olga Charlat; Elizabeth Wiellette; Yue Zhang; Stephanie Wiessner; Marc Hild; Xiaoying Shi; Christopher J Wilson; Craig Mickanin; Vic Myer; Aleem Fazal; Ronald Tomlinson; Fabrizio Serluca; Wenlin Shao; Hong Cheng; Michael Shultz; Christina Rau; Markus Schirle; Judith Schlegl; Sonja Ghidelli; Stephen Fawell; Chris Lu; Daniel Curtis; Marc W Kirschner; Christoph Lengauer; Peter M Finan; John A Tallarico; Tewis Bouwmeester; Jeffery A Porter; Andreas Bauer; Feng Cong
Journal:  Nature       Date:  2009-09-16       Impact factor: 49.962

8.  Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

Authors:  Huw D Thomas; Christopher R Calabrese; Michael A Batey; Stacie Canan; Zdenek Hostomsky; Suzanne Kyle; Karen A Maegley; David R Newell; Donald Skalitzky; Lan-Zhen Wang; Stephen E Webber; Nicola J Curtin
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

Review 9.  Toward a unified nomenclature for mammalian ADP-ribosyltransferases.

Authors:  Michael O Hottiger; Paul O Hassa; Bernhard Lüscher; Herwig Schüler; Friedrich Koch-Nolte
Journal:  Trends Biochem Sci       Date:  2010-01-26       Impact factor: 13.807

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245
  10 in total
  1 in total

1.  Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.

Authors:  Jing Niu; Christie Scheuerell; Shailly Mehrotra; Sharon Karan; Shannon Puhalla; Brian F Kiesel; Jiuping Ji; Edward Chu; Mathangi Gopalakrishnan; Vijay Ivaturi; Jogarao Gobburu; Jan H Beumer
Journal:  J Clin Pharmacol       Date:  2017-04-07       Impact factor: 3.126
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.